US EditionStandardized Brain Cell Atlas to Accelerate Parkinson's and Alzheimer's Research
INDIANA UNIVERSITY SCHOOL OF MEDICINE, JUL 14 – Researchers used AI and proteomics to identify 30 potential 3-secretase targets, advancing precision Alzheimer’s therapies with a $41.6 million NIH grant backing this effort.
- On July 17, 2025, ASAP and the Allen Institute collaborated to enhance the Allen Brain Cell Atlas by incorporating Parkinson's disease data, providing researchers worldwide with advanced tools to study neurodegenerative disorders.
- This collaboration follows growing demands to replace traditional drug discovery with AI-driven approaches amid rising neurodegenerative disease burdens and limited access to patient brain samples.
- The expanded Atlas now integrates 3 million Parkinson's patient cells with 6.4 million existing brain cells, enabling cross-disease analysis of shared cell types and molecular programs.
- Tyler Mollenkopf emphasized that single-cell genomics has greatly advanced the study of brain cell diversity, underscoring the significance of integrating ASAP's Parkinson's data.
- This effort aims to accelerate targeted therapies and biomarker discovery by setting a new standard for characterizing disease-specific brain changes across Parkinson's, Alzheimer's, and related disorders.
21 Articles
21 Articles
Cambridge Times
Waterloo ChronicleAt the Library: ‘Tangles: A story about Alzheimer’s, my mother, and me’ by Sarah Leavitt
Sarah Leavitt’s ‘Tangles’ is a heartfelt graphic memoir that explores her mother’s experience with Alzheimer’s through honest storytelling and expressive illustration.
Standardized brain cell atlas to accelerate Parkinson's and Alzheimer's research
Researchers now have a powerful new way to understand the types of brain cells that are affected in neurodegenerative diseases and to uncover connections between conditions such as Parkinson's, Alzheimer's, and other forms of dementia.
Thanks to this international collaboration, researchers have begun to unravel the complex molecular landscape of neurodegeneration, which offers hope for early diagnosis and more specific therapies.
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging
More than 57 million people globally suffer from neurodegenerative diseases, a figure expected to double every 20 years. Despite this growing burden, there are currently no cures, and treatment options remain limited due to disease heterogeneity, prolonged preclinical and prodromal phases, poor understanding of disease mechanisms, and diagnostic challenges. Identifying novel biomarkers is crucial for improving early detection, prognosis, staging…
(Seoul = Yonhap News) Reporter Lee Ju-young = It will be used for biological basic research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and aging, as well as early diagnosis and treatment development...
An international collaboration carries out the largest analysis with hundreds of millions of samples, which it will share with researchers around the world, to understand neurodegenerative diseases
Coverage Details
Bias Distribution
- 50% of the sources lean Left
To view factuality data please Upgrade to Premium
